|
業務類別
|
Biotechnology |
|
業務概覽
|
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders. |
| 公司地址
| 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 333-5280 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.contineum-tx.com |
| 員工數量
| 51 |
| Mr. Carmine Stengone |
Chief Executive Officer, President and Director |
美元 608.12K |
05/03/2026 |
| Mr. Daniel S. Lorrain, PhD |
Chief Science Officer |
-- |
29/04/2025 |
| Mr. John Stephen Healy |
General Counsel and Corporate Secretary |
-- |
29/04/2025 |
| Mr. Tim Watkins |
Chief Medical Officer and Head of Development |
-- |
29/04/2025 |
| Mr. Peter T. Slover |
Chief Financial Officer and Principal Accounting Officer |
-- |
05/03/2026 |
|
|
| Ms. Olivia C. Ware, M.B.A. |
Independent Director |
05/03/2026 |
| Ms. Lori Lyons-Williams |
Independent Director |
05/03/2026 |
| Mr. Evert B. Schimmelpennink |
Chairman of the Board |
05/03/2026 |
| Mr. Carmine Stengone |
Chief Executive Officer, President and Director |
05/03/2026 |
| Ms. Sarah Boyce |
Independent Director |
05/03/2026 |
| Dr. Diego Miralles, M.D. |
Director |
05/03/2026 |
| Dr. Todd C. Brady, M.D.,PhD |
Independent Director |
05/03/2026 |
| Mr. Troy A. Ignelzi |
Independent Director |
05/03/2026 |
|
|
|
|
